3K3A-APC

**3K3A-APC** is a genetically engineered recombinant variant of human activated protein C (APC), designed to enhance the cytoprotective and anti-inflammatory activities of APC while greatly reducing its anticoagulant activity. The drug was developed primarily for the treatment of acute ischemic stroke, with additional investigation in Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and diabetic foot ulcers. Mechanistically, it acts as a modulator at protease activated receptors (PARs), especially PAR1 and PAR3, as well as inhibiting coagulation factors V and VIII. Preclinical studies suggest that it crosses the blood-brain barrier via endothelial protein C receptor (EPCR) transport, reduces inflammation, protects vascular integrity, and improves neurological outcomes in models of neurodegeneration and stroke[1][2][5]. Clinical trials have shown reduced hemorrhage rates in stroke patients treated with 3K3A‑APC compared to placebo[8]. The drug was developed by ZZ Biotech in collaboration with The Scripps Research Institute and University of Southern California.

Other names

3K3A non-anticoagulant mutantRecombinant variant of human activated protein C